Moneycontrol
Jan 01, 2013 05:32 PM IST | Source: Moneycontrol.com

Aurobindo closes up 2% on approvals for Rizatriptan

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.

Aurobindo closes up 2% on approvals for Rizatriptan

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.


The company said the product was ready for launch. "Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and company's Maxalt tablets and is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 6 to 17 years old," Aurobindo said in a release.


The annual sale of product is approximately USD 300 million for 12 months ending March 2012, according to IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.


Aurobindo has a total of 171 ANDA approvals from USFDA.

Also Read
M&M Dec auto sales up 6% to 45,297 units
Etihad board to consider investment in Kingfisher, Jet

X
Sections
Follow us on
Available On